Natriuretic peptides: Novel therapeutic targets in heart failure

Journal of Investigative Medicine

Volumn 53, Issue 7, 2005, Pages 378-384

  Cataliotti, Alessandro ^a   Burnett Jr , John C ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aldosterone; Atrial natriuretic peptide; Brain natriuretic peptide; Particulate guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; OMAPATRILAT; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URODILATIN;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; HEART DISEASE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PROTEIN FUNCTION; RENAL PROTECTION;

EID: 29144468019     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (75)

1. de Bold A, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;322:78-81.
3. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
4. Stingo AJ, Clavell AL, Heublein DM, et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992;263:1318-21.
5. Suga SI, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system." J Clin Invest 1992;90:1145-9.
6. Kuhn M. Molecular physiology of natriuretic peptide signaling. Basic Res Cardiol 2004;99:76-82.
7. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996;271:R373-80.
8. Burnett JC Jr, Granger JP, Opgenorth TF. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984;247:F863-6.
9. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A 1996;93:6215-9.
10. Wright RS, Wei CM, Kim CH, et al. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol 1996;28:1031-8.
11. Lainchbury JG, Burnett JC Jr, Meyer D, Redfield MM. Effects of the natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol 2000;278:H33-40.
12. Stevens TL, Rasmussen TE, Wei C-M, et al. Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. J Card Fail 1996;2:119-25.
13. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist forguanylate cyclase-coupled receptors. Circulation 1994;89:2232-40.
14. Lee S-C, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-54.
15. Yamamoto K, Burnett JC Jr, Redfield MM. Effects of endogenous natriuretic peptide system on ventricular and coronary function in the failing canine heart. Am J Physiol 1997;273:H2406-14.
16. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Invest Drugs 2001;10:935-42.
17. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Invest Drugs 2004;13:643-52.
18. Chen HH, Burnett JC. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999;111:406-16.
19. Colucci WS, Elkayam U, Horton DP, et al, The Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
20. Marcus LS, Hart D, Packer Yushak M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind placebo controlled, randomized crossover trial. Circulation 1996;94:3184-9.
21. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute Heart CHF). Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
22. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1997;32 Suppl 3:S22-8.
23. Chen HH, Cataliotti A, Schirger JA, et al. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2005;288:R1093-7.
24. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
25. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
26. Margulies KB, Perrella MA, Heublein DM, Burnett JC Jr. ANF-mediated renal cyclic GMP generation in congestive heart failure. Am J Physiol 1991;260:F562-8.
27. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-5.
28. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
29. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5.
30. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and anti-aldosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005;67:1723-30.
31. Kudo T, Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 1984;312:756-7.
32. Higuchi K, Hashiguchi T, Ohashi M, et al. Porcine brain natriuretic peptide receptor in bovine adrenal cortex. Life Sci 1989;44:881-6.
33. Chartier L, Schiffrin E, Thibault G, Garcia R. Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 1984;115:2026-8.
34. Nawata H, Ohashi M, Haji M, et al. Atrial and brain natriuretic peptide in adrenal steroidogenesis. J Steroid Biochem Mol Biol 1991;40:367-79.
35. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure. Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.
36. Chen HH, Grantham A, Schirger J, et al. Subcutaneous administration of BNP in experimental heart failure. J Am Coll Cardiol 2000;36:1706-12.
37. Chen HH, Redfield MM, Nordstrom LJ, et al. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004;10:115-9.
38. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004;109:1680-5.
39. Cataliotti A, Chen HH, Harty GJ, et al. Differential cardiorenal and humoral actions of a vasopeptidase inhibitor compared to ACE inhibitor and diuretic in experimental mild CHF. Circulation 2002;105:639-44.
40. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-8.
41. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-7.
42. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type-1 turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-35.
43. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999;138(2 Pt 1):285-90.
44. Greenberg A. Diuretic complications. Am J Med Sci 2000;319:10-24.
45. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6.
46. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-5.
47. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686-9.
48. Cataliotti A, Schirger JA, Martin FL, et al. Oral human BNP activates cGMP and decreases mean arterial pressure. Circulation 2005;112:836-40.
49. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
50. Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail 1996;2(4 Suppl):S277-85.
51. Michaels AD, Klein A, Madden JA, Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-701.
52. Burlew B, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002;27:92-8.
53. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008.
54. Manabe I, Shido T, Nagai R. Gene expression in fibroblasts and fibrosis. Circ Res 2002;91:1103-13.
55. Kohl P. Heterogenous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ Res 2003;93:381-3.
56. Cha Y-M, Dzeja PP, Shen WK, et al. Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. Am J Physiol Heart Circ Physiol 2003;284:H1313-20.
57. Vliegen HW, van der Laarse A, Cornelisse CJ, Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation. Eur Heart J 1991;12:488-94.
58. Frank JS, Langer GA. The myocardial interstitium: its structure and its role in ionic exchange. J Cell Biol 1974;60:586-601.
59. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-30.
60. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004;9:53-60.
61. Guarda E, Myers PR, Brilla CG, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:1004-8.
62. Fullerton MJ, Funder JW. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1994;28:1863-7.
63. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
64. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-92.
65. Brilla CG, Rupp H, Funck R, Maisch B. Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995;16 Suppl O:107-9.
66. Pitt B, Zannad F, Remme WJ, et al, for The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 2001;341:709-17.
67. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering with the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001;38:1227-32.
68. Pitt B, Remme W, Zannad F, et al, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
69. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-34.
70. Kapoun A, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-61.
71. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-407.
72. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97:4239-44.
73. Fujisaki H, Itoh H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-65.
74. Horio T, Tokodume T, Maki T, et al. Gene expression, secretion, and autocrine actions of C-type natriuretic peptide in cultured adult rat cardiac fibrosis. Endocrinology 2003;144:2279-84.
75. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-8.